Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.23 Consensus Target Price from Brokerages

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have been given an average rating of “Hold” by the six brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $3.2250.

A number of research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Lexicon Pharmaceuticals by 7.6% during the third quarter. Vanguard Group Inc. now owns 9,521,874 shares of the biopharmaceutical company’s stock worth $12,855,000 after acquiring an additional 670,838 shares in the last quarter. Millennium Management LLC raised its stake in shares of Lexicon Pharmaceuticals by 133.1% during the 3rd quarter. Millennium Management LLC now owns 3,830,660 shares of the biopharmaceutical company’s stock valued at $5,171,000 after purchasing an additional 2,187,396 shares during the period. UBS Group AG lifted its holdings in Lexicon Pharmaceuticals by 752.1% during the 4th quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company’s stock worth $3,458,000 after purchasing an additional 2,654,315 shares in the last quarter. CIBC Bancorp USA Inc. bought a new position in Lexicon Pharmaceuticals in the 3rd quarter worth about $3,240,000. Finally, AQR Capital Management LLC purchased a new position in Lexicon Pharmaceuticals during the 1st quarter valued at about $541,000. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Stock Down 19.4%

LXRX opened at $1.16 on Monday. Lexicon Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $1.83. The company’s 50-day moving average price is $1.31 and its two-hundred day moving average price is $1.28. The stock has a market cap of $421.63 million, a price-to-earnings ratio of -6.11 and a beta of 0.98. The company has a quick ratio of 5.63, a current ratio of 5.64 and a debt-to-equity ratio of 0.47.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. The company had revenue of $14.18 million for the quarter, compared to analysts’ expectations of $5.81 million. As a group, equities analysts expect that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.